Dr. Brayer on Alternatives to CAR T-Cell Therapy in Multiple Myeloma

Partner | Cancer Centers | <b>Moffitt</b>

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Jason Brayer, MD, PhD, assistant member, malignant hematology program at Moffitt Cancer Center, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Because some patients with multiple myeloma do not have access to, or are ineligible for, CAR T-cell therapy, T-cell–redirecting therapies could potentially address an important unmet need in this population, according to Brayer. It is important that these patients know that other options can provide robust responses, similar to those achieved with CAR T cells, Brayer says. 

Once the toxicities of bispecific T-cell engagers and bispecific antibodies are managed, and they can be delivered to patients safely, these treatments could represent more accessible options for use in a community-based setting, Brayer concludes.